Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
EMERGENCY OXERVATE EYE MEDICATION is a federal award for 242-Network Contract Office 02 (36C242) held by Dompe U.S. Inc. Estimated value $144K ($144K obligated). Current period of performance ends Jun 27, 2022. Last award drew 1 bidder. Place of performance: SAN MATEO CA.
Recompete timing
PublicCurrent PoP ended Jun 27, 2022 (1516 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C24222N0420?
36C24222N0420 (Emergency oxervate EYE medication) is a 242-Network Contract Office 02 (36C242) award with a potential value of $144K, currently held by Dompe U.S. Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C242-22-N-0420?
36C242-22-N-0420 is the dashed form of PIID 36C24222N0420 (Emergency oxervate EYE medication), held by Dompe U.S. Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C24222N0420?
242-Network Contract Office 02 (36C242) awarded 36C24222N0420 to Dompe U.S. Inc (potential $144K).
Who is the incumbent on 36C24222N0420?
Dompe U.S. Inc is the incumbent. The current period of performance ends Jun 27, 2022.
When does Dompe U.S. Inc’s 36C24222N0420 come up for recompete?
SCOUT tracks a period-of-performance end of Jun 27, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.